Kenny Walter

Individuals with comorbid asthma, allergic rhinitis, and oral allergy syndrome had higher rates of eosinophilic esophagitis.

Antibiotic use was not linked to a decrease in infectious complications in either the unadjusted analysis or the adjusted analysis.

The results show methotrexate exposure time and cumulative doses were not predictors for fibrosis, but alcohol was a predictor.

There was no association with microbiome-disturbing agents, but laxatives and antibiotics were independently associated with a more than 2-fold increase in the risk of acquiring an infection.

The most common invasive fungal infection was histoplasmosis and the risk of invasive fungal infections was more than double in patients treated with corticosteroids than it was for patients treated with anti-TNFs.

The results show a placebo-controlled trial is warranted in the future.

Electroacupuncture also resulted in a greater relief for the majority of OIC symptoms and improved the quality of life for this patient population and had no effects on cancer pain and its opioid treatment dosage.

Patients who were PCR positive or likely colonized in the two-step era were 20 times less likely to be associated with treatment for CDI, without adversely impacting patient outcomes.

FMT was cost-effective compared to vancomycin in both the general CDI population, as well as the subset of patients with IBD. However, it was less cost-effective in compared to fidaxomicin.

There was a 2.35-fold risk increase in PCCRC in the lowest ADR group compared to the highest.

HCV RNA positivity was significantly more prevalent in the male patient than it was for females in both adults and the general population after excluding high-risk groups.

There were no serious adverse events in the group of patients treated with colesevelam.

HCV RNA positivity was significantly more prevalent in the male patient than it was for females in both adults and the general population after excluding high-risk groups.

Acceptability of the vaccine was high among the completers and some non-completers that felt it was safe and offered them protection.

There have been only 12 unique studies evaluating this treatment for the primary and secondary prevention of CDI, with only 1 conducted prospectively.

Only 2 of the households sampled featured an owner and pet who both tested positive for C. difficile.

The treatment was well-tolerated, with all serious treatment emergent adverse events considered not related to the treatment.

The results show the ADR in the early session of the unassisted group was significantly higher compared to those in the late session.

The results show 2.56% of the CDI group developed prostate cancer, compared to 7.79% in the control group in patients matched by age range and Charlson Comorbidity Index.

The treatment, developed by Pfizer, has been approved by the FDA for adult patients with atopic dermatitis.

Exposure to maternal, paternal, or full sibling major depression was associated with a two-fold higher risk of major depression for men.

Standard infusion group had more patients with P. aeruginosa isolates from blood and respiratory cultures, ICU status at the start of therapy and longer duration of treatment.

Sofosbuvir-based regimens were the most commonly prescribed therapies to treat hepatitis C virus in Asia, Africa, and the Commonwealth of Independent States.

The results show adherence to 6 quality indicators was linked to improvements in the post-intervention cohort with significant increases in C difficile testing, CRP testing, testing for latent tuberculosis, thromboprophylaxis, adequate corticosteroids prescription, and limitation of narcotics prescribed.

The connection between different ADHD subtypes and mood disorders has not been fully explored.

Latino-English preferred patients had an overall lower rate of screening compared to both non-Hispanic whites and Latino-Spanish preferred patients.

The results also show a decrease in antibiotic use, hospital length of stay, and overall cost to the patient.

The treatment is a novel, investigational anti-C5 recycling monoclonal antibody showing promise for treating patients with paroxysmal nocturnal hemoglobinuria.

Thus far, the phase 2 data on CP101 was generally positive for the treatment of recurrent C difficile infections.

Singh presented during the recent APSARD conference. onthe topic of ADHD and bipolar disorder.